Epadol Neo soft capsules 60 pcs.

Active ingredient: 1 capsule contains 1000 mg of omega-3 acid ethyl esters, which include:

• Eicosapentaenoic acid 300 mg;
• docosahexaenoic acid 200 mg;
• other fatty acids – 498 mg;
• d-α-tocopherol (vitamin E) 2 mg;
• Excipients: gelatin, glycerin (as part of the gelatin capsule shell).

Epadol Neo can be purchased through the MIS Pharmacy 9-1-1 website at an attractive price.
Epadol Neo instructions for use and Epadol Neo price are listed in the catalog of the MIS Pharmacy 9-1-1 website.

Soft capsules.

Main physicochemical properties: soft gelatin capsules from light yellow to dark yellow, oval in shape with a seam. The contents of the capsule are an oily liquid from light yellow to dark yellow with a specific odor.

You can buy Epadol Neo tablets through the MIS Pharmacy 9-1-1 website at an attractive price.
The current price for the medication is indicated in the catalog of the MIS Pharmacy 9-1-1 website.

Omega-3 triglycerides, including other esters and acids. ATC code C10A X06.

Pharmacodynamics. Omega-3 polyunsaturated fatty acids – eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) – are essential fatty acids. The drug actively affects blood plasma lipids, reducing the level of triglycerides, LDL and VLDL. The drug affects hemostasis and reduces the risk of thrombosis by affecting the aggregation ability of platelets; moderately reduces blood pressure. Normalization of the blood lipid spectrum also occurs due to a decrease in the synthesis of triglycerides in the liver, since EPA and DHA inhibit the esterification of other fatty acids, as well as due to a decrease in the number of free fatty acids (the number of peroxisomes β-oxidation of fatty acids increases), which are involved in the synthesis of triglycerides. A decrease in the synthesis of triglycerides leads to a decrease in the level of VLDL.

The drug actively affects blood plasma lipids, reducing the level of triglycerides, low-density lipoproteins and very low-density lipoproteins (LDL). The drug affects hemostasis and reduces the risk of thrombosis by affecting the aggregation ability of platelets; moderately reduces blood pressure.

α-Tocopherol is an antioxidant that prevents the oxidation of polyunsaturated fatty acids.

Pharmacokinetics: No pharmacokinetic data are available.

For primary prevention of atherosclerosis and cardiovascular diseases; as part of complex therapy for atherosclerosis, coronary heart disease, and angina; for secondary prevention of myocardial infarction in addition to standard treatment methods (e.g. statins, antiplatelet agents, β-adrenoceptor blockers, ACE inhibitors); for hypertriglyceridemia in addition to diet therapy, if the latter is not effective enough.

The drug is taken with meals.

For the purpose of prevention, adults and children over 12 years of age are prescribed 1 capsule per day. According to individual indications, the dose of the drug can be increased to 2 capsules per day.

In the complex therapy of cardiovascular diseases – 2 capsules per day.

In hypertriglyceridemia, the initial dose is 2 capsules per day (in 1 or 2 doses). In case of insufficient effect, the dose of the drug is increased to 4 capsules per day. Treatment should be continued until the desired therapeutic effect is achieved.

Increased individual sensitivity to any of the components of the drug. exacerbation of chronic cholecystitis and chronic pancreatitis, exacerbation of diseases of the hepatobiliary system, cholelithiasis, pathological conditions accompanied by hemorrhagic syndrome.

Immune system disorders: hypersensitivity reactions.

Metabolism and nutrition disorders: hyperglycemia.

From the nervous system: dizziness, dysgeusia, headache.

Vascular disorders: hypotension.

From the blood and lymphatic system: hemorrhagic diathesis.

Respiratory, thoracic and mediastinal disorders: dryness of the nasal mucosa.

Gastrointestinal: dyspeptic disorders, nausea, abdominal pain, gastrointestinal disorders (gastroesophageal reflux, belching, vomiting, flatulence, diarrhea, constipation), gastritis, gastroenteritis, bleeding from the lower digestive tract.

Hepatobiliary system: liver dysfunction.

Skin and subcutaneous tissue disorders: skin rash, itching, redness of the skin, urticaria, acne.

Laboratory indicators: increased leukocyte count, LDH level in the blood, increased transaminase activity.

In the event of a moderate increase in bleeding time (when using the drug in high doses, i.e. 4 capsules per day), it is necessary to monitor the condition of patients receiving anticoagulant therapy and, if necessary, adjust the dose of the anticoagulant accordingly. It is necessary to take into account the possibility of an increase in bleeding time in patients with an increased risk of hemorrhage (due to severe trauma, surgery or other reasons).

The drug should not be prescribed for the treatment of exogenous hypertriglyceridemia (type I hyperchylomicronemia).

In patients with hepatic insufficiency (especially when taking high doses of the drug), regular monitoring of liver function (ALT and AST) is necessary.

The likelihood of side effects is reduced when the drug is taken with food.

Use during pregnancy and breastfeeding. The use of the drug during pregnancy is possible only as prescribed by a doctor, taking into account the risk / benefit ratio. During breastfeeding, the drug can be used after consulting a doctor.

The ability to influence the reaction speed when driving vehicles or working with other mechanisms. Does not affect.

Children. Due to the lack of data on efficacy and safety, the drug is not used in children under 12 years of age.

It is not recommended to prescribe together with fibrates due to the lack of clinical experience. The appointment of Epadol-neo simultaneously with warfarin does not lead to hemorrhagic complications, however, in the case of combined use of these drugs or discontinuation of treatment with Epadol-neo, prothrombin time should be monitored.

In case of overdose, allergic reactions similar to those observed with side effects may occur. Treatment: symptomatic therapy.

In the original packaging at a temperature not exceeding 25 °C.

5 capsules in a blister; 6 blisters in a pack.

5 capsules in a blister; 12 blisters in a pack.

10 capsules in a blister; 3 blisters in a pack.

10 capsules in a blister; 6 blisters in a pack.